Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
aerosolized, aid, alter, antibacterial, atrial, autoimmune, bifurcation, breakthrough, buy, cancer, cardiovascular, cell, CHF, codification, codified, composition, confirming, consummated, dissolution, effort, episode, exceeded, fibrillation, flecainide, fluctuate, Gate, GP, hydroxychloroquine, ID, ImaginAb, imaging, InCarda, InRhythm, ISO, ISP, lag, lesser, light, lock, LP, methodology, molecular, NaN, Nanolive, neurologic, oEvaluating, oFor, oIf, oObtaining, oReading, paroxysmal, partnership, peer, platform, promissory, psychiatric, Pulmoquine, reconsideration, representation, SA, Sarissa, shadow, simulation, SPAC, stake, Subtopic, tranche, unconsolidated, verify
Removed:
agent, knowledge
Filing tables
Filing exhibits
INVA similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARMATA PHARMACEUTICALS, INC.
We consent to the use of our report dated March 17, 2022, with respect to the consolidated financial statements of Armata Pharmaceuticals, Inc., included in the Annual Report (Form 10-K/A) of Innoviva, Inc. for the year ended December 31, 2021, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
San Diego, California
March 17, 2022